venglustat: Clinical Trials

5 trials of venglustat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated, 1 active not recruiting. 5 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Completed 2, Terminated 2, Active not recruiting 1
Phase 31Terminated 1

Follow venglustat: new trials by email Literature Review of venglustat trials Research Report on venglustat

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
Venglustat, Placebo - Polycystic Kidney, Autosomal Dominant
Phase 2 / Phase 3TerminatedGenzyme, a Sanofi Company4782018-10-042023-02-03
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension
venglustat (GZ402671), imiglucerase - Gaucher Disease Type 1, Gaucher Disease Type 3
Phase 2Active not recruitingGenzyme, a Sanofi Company122017-01-042026-07-10
A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation
venglustat GZ/SAR402671, Placebo - Parkinson's Disease
Phase 2TerminatedGenzyme, a Sanofi Company2732016-12-152022-05-24
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease
GZ/SAR402671 - Fabry Disease
Phase 2CompletedGenzyme, a Sanofi Company82015-07-072021-03-23
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease
GZ/SAR402671 - Fabry Disease
Phase 2CompletedGenzyme, a Sanofi Company112014-11-012019-12-17

Conditions studied

Fabry Disease (2)  ·  Gaucher Disease (1)  ·  Parkinson Disease (1)  ·  Polycystic Kidney, Autosomal Dominant (1)

Sponsors

Genzyme, a Sanofi Company (5)

Countries

United Kingdom (5)  ·  United States (5)  ·  France (4)  ·  Germany (3)  ·  Japan (3)  ·  Poland (3)  ·  Austria (2)  ·  Canada (2)  ·  Israel (2)  ·  Italy (2)  ·  Portugal (2)  ·  Russia (2)  ·  Spain (2)  ·  Taiwan (2)  ·  Argentina (1)

Results publications

PMID 36481125, PMID 34897099, PMID 36204243, PMID 36535535, PMID 37050861, PMID 37479372, PMID 38802634, PMID 39356039

NIH funding

2014 (2), 2016 (1), 2017 (1), 2023 (1)